These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 39107157)

  • 1. Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results.
    Nathan P; Venugopal B; Ali J; Allison J; Ceruso M; Charnley N; Griffiths R; Michael A; Moore K; Perrot V; Prendergast Á; Sharma A; Szabados B; Larkin J
    Clin Genitourin Cancer; 2024 Oct; 22(5):102141. PubMed ID: 39107157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
    Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor.
    Gebrael G; Jo Y; Mathew Thomas V; Li H; Sayegh N; Tripathi N; Srivastava A; Nordblad B; Dal E; Narang A; Brundage J; Campbell P; Galarza Fortuna G; Hage Chehade C; Maughan BL; Agarwal N; Swami U
    Cancer; 2024 Aug; 130(15):2621-2628. PubMed ID: 38564301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
    McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
    Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
    Albiges L; Schmidinger M; Taguieva-Pioger N; Perol D; Grünwald V; Guemas E
    Future Oncol; 2022 Mar; 18(8):915-926. PubMed ID: 34911359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Navani V; Wells JC; Boyne DJ; Cheung WY; Brenner DM; McGregor BA; Labaki C; Schmidt AL; McKay RR; Meza L; Pal SK; Donskov F; Beuselinck B; Otiato M; Ludwig L; Powles T; Szabados BE; Choueiri TK; Heng DYC
    Clin Genitourin Cancer; 2023 Feb; 21(1):106.e1-106.e8. PubMed ID: 35945133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
    Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy.
    Ishihara H; Kondo T; Yoshida K; Omae K; Takagi T; Iizuka J; Tanabe K
    Urol Oncol; 2017 Sep; 35(9):542.e1-542.e9. PubMed ID: 28619633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data.
    Tomida R; Takahashi M; Matsushita Y; Kojima T; Yamana K; Kandori S; Bando Y; Nishiyama N; Yamashita S; Taniguchi H; Monji K; Ishiyama R; Tatarano S; Masui K; Matsuda A; Kaneko T; Motoshima T; Shiraishi Y; Kira S; Murashima T; Hara H; Matsumura M; Kitamura H; Miyake H; Furukawa J;
    Clin Genitourin Cancer; 2024 Jun; 22(3):102094. PubMed ID: 38714434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final Analysis of a Noninterventional Study on Cabozantinib in Patients With Advanced Renal Cell Carcinoma After Prior Checkpoint Inhibitor Therapy of the German Interdisciplinary Working Group on Renal Tumors (IAG-N).
    Viktor G; Martin B; Mohammad-Reza R; Günter N; Marco S; Anne F; Michael M; Christoph M; Mark-Oliver Z; Anke W; Andreas H; Jochen C; C D; Thomas H; M S; Disorn S; Philipp I
    Clin Genitourin Cancer; 2024 Oct; 22(5):102159. PubMed ID: 39095295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
    Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
    Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of cabozantinib and immune checkpoint inhibitors in advanced renal cell carcinoma: update from the European Society for Medical Oncology 2020.
    Sarkis J; Khalil N; Alkassis M
    Future Oncol; 2021 Mar; 17(9):991-992. PubMed ID: 33533650
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer.
    Bauman JR; Liu G; Preeshagul I; Liu SV; Melosky B; Abrahami D; Li B; Thomaidou D; Duncan K; Krulewicz S; Rupp M; Lin JJ
    Lung Cancer; 2024 Sep; 195():107919. PubMed ID: 39197358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
    Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
    Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
    Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
    Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
    Martínez Chanzá N; Xie W; Asim Bilen M; Dzimitrowicz H; Burkart J; Geynisman DM; Balakrishnan A; Bowman IA; Jain R; Stadler W; Zakharia Y; Narayan V; Beuselinck B; McKay RR; Tripathi A; Pachynski R; Hahn AW; Hsu J; Shah SA; Lam ET; Rose TL; Mega AE; Vogelzang N; Harrison MR; Mortazavi A; Plimack ER; Vaishampayan U; Hammers H; George S; Haas N; Agarwal N; Pal SK; Srinivas S; Carneiro BA; Heng DYC; Bosse D; Choueiri TK; Harshman LC
    Lancet Oncol; 2019 Apr; 20(4):581-590. PubMed ID: 30827746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis).
    Graham J; Ghosh S; Breau RH; Wood L; Tanguay S; Bosse D; Lalani AK; Bhindi B; Heng D; Finelli A; Fallah-Rad N; Castonguay V; Basappa NS; Soulières D; Pouliot F; Kollmannsberger C; Bjarnason GA
    Clin Genitourin Cancer; 2024 Jun; 22(3):102060. PubMed ID: 38521648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
    Amzal B; Fu S; Meng J; Lister J; Karcher H
    PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study.
    Waddell T; Fife K; Griffiths R; Sharma A; Dhokia P; Groves L; Hurst M; Tsang C; Sugrue D; McKenna S; Houghton J; Carroll R
    BMC Cancer; 2022 Jun; 22(1):617. PubMed ID: 35668384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.